10x Genomics (TXG) Q2 FY26 earnings call

10x Genomics delivered a solid Q2 FY26, highlighted by the exceptional customer reception and order volume for its new Atera platform, which is poised to transform spatial biology. While instrument sales saw a temporary decline due to the Atera transition, consumables maintained strong growth, particularly in Spatial. The company is leveraging its technology to capitalize on the growing demand for high-quality biological data driven by AI, reinforcing its long-term strategic positioning despite near-term market dynamics.